ISS Backs NovaBay's Avenova Sale Proposals

TL;DR

ISS recommends shareholders vote YES on selling Avenova. Big move for NovaBay.

AI Summary

NovaBay Pharmaceuticals, Inc. filed a DEFA14A on November 15, 2024, related to its upcoming shareholder meeting. The filing highlights that the prominent proxy advisory firm ISS supports NovaBay's proposals, specifically those authorizing the sale of its Avenova brand. This indicates a positive recommendation from ISS regarding the company's strategic direction.

Why It Matters

This filing signals potential shareholder approval for a significant strategic move, the sale of a key brand, which could impact the company's future revenue streams and market position.

Risk Assessment

Risk Level: low — The filing is a routine proxy statement and does not contain immediate financial risks, but rather outlines proposals for shareholder consideration.

Key Players & Entities

• NovaBay Pharmaceuticals, Inc. (company) — Registrant
• ISS (company) — Proxy Advisory Firm
• Avenova (company) — Brand

FAQ

Key Financial Figures

• $11.5 million — ls, LLC ("PRN") for a purchase price of $11.5 million in cash, subject to adjustment, and the

Filing Documents

• nby20241114_defa14a.htm (DEFA14A) — 26KB
• nb.jpg (GRAPHIC) — 6KB
• 0001437749-24-035432.txt ( ) — 35KB

Forward-Looking Statements

Forward-Looking Statements This release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. These forward-looking statements are based upon the Company and its management's current expectations, assumptions, estimates, projections and beliefs. Such statements include, but are not limited to, statements regarding the contemplated transaction with PRN (including the Asset Purchase Agreement, by and between PRN and the Company, dated as of September 19, 2024 and as amended on November 5, 2024), the potential liquidation and dissolution of the Company and related matters. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in, or implied by, these forward-looking statements. Other risks relating to NovaBay's business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in the Company's latest Form 10-K, subsequent Forms 10-Q and/or Form 8-K filings with the SEC and the Special Meeting Proxy Statement, as supplemented including by the Supplement to the Special Meeting Proxy Statement dated as of November 12, 2024, especially under the heading "Risk Factors." The forward-looking statements in this release speak only as of this date, and the Company disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law. Additional Information and Where to Find It In connection with the solicitation of proxies, on October 16, 2024, NovaBay filed the Special Meeting Proxy Statement with the SE

View Full Filing

View this DEFA14A filing on SEC EDGAR